Document is current

Article History

Accepted: 20 January 2025

First Online: 7 March 2025

Declarations

:

: Not applicable for this literature review.

: B.L.Z has served as a consultant for CSL Behring, KalVista, and BioCryst, on the DMSB for CSL Behring and BioMarin, and has had a laboratory service agreement with Ionis.K.B. reports no conflicts in relation to this manuscript.L.B. has consulted/served as speaker for, engaged in research and educational projects with or accepted travel grants from the following companies: BioCryst, CSL Behring, Takeda, Novartis, GSK, Blueprint, Kalvista, Pharvaris.S.C.C. has served on medical advisory boards for BioCryst, KalVista, and CSL Behring. She is a member of the Medical Advisory Board of the US HAEA.H.F. has received speaker fee and travel grants from CSL Behring, Pharming, Takeda, KalVista, and Pharvaris and served as an advisor/consultant for these companies and for Astria, BioCryst, Intellia, Ionis, and ONO Pharmaceutical.A.E.G. reports no conflicts in relation to this manuscript.A.S.G. receives a productivity grant from National Council of Research (CNPq) and a grant from researcher initiative from Shire/Takeda. A.S.G. reports speaking and/or consultancy fees from Catalyst, CSL Behring, Exeltis, KalVista, Multicare, Pharvaris, Pint-pharma, and Takeda.A.K. reports no conflicts in relation to this manuscript.A.L.L. reports conference travel support and speaking fees from Takeda and CSL Behring.M.Ml. reports honoraria or consultation fees from Astria, BioCryst, CSL Behring, Intellia, KalVista, Pharvaris, Shire/Takeda.M.A.R. has served as a research investigator for BioCryst, BioMarin, CSL Behring, Ionis, KalVista, Pharvaris, Takeda and a consultant for Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, KalVista, Pfizer, Pharming, Pharvaris, Sanofi-Regeneron, Takeda.A.A. reports conference travel support and/or honoraria from BioCryst, CSL Behring, Intellia, and Takeda, and clinical trial support from Astria, CSL Behring, Ionis, KalVista, Octapharma, Pharvaris, and Takeda, outside of the submitted work.A.B. reports research funding from Ionis, Astria, and Intellia, and advisory boards with CSL Behring, Ionis, Pharvaris, Intellia, KalVista, Astria, Takeda.S.B. reports speaker and/or advisor fees from Astria, BioCryst, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharvaris, and Takeda, and research funding from CSL Behring and Takeda. Chair of the Canadian Hereditary Angioedema Network.I.B-G. is or recently was a speaker, advisor, engaged in research and educational projects, and/or received research and consultancy grants from Takeda, CSL Behring, Pharming, KalVista, Pharvaris, and BioCryst.M.B. reports conference travel support and research/advisory fees from Takeda, KalVista, and CSL Behring.H.B.B. reports no conflicts in relation to this manuscript.T.C. is or recently was a speaker, advisor, engaged in research and educational projects, received research grants and/or received funding to attend conferences and educational events from Astria, BioCryst, CSL Behring, IONIS, KalVista, Novartis, Otsuka, Pharming, Pharvaris, and Takeda. She is a researcher in the Hospital La Paz Institute for Health Research (IdiPAZ) program for promoting research activities.M.C. received grant research support and/or speaker/consultancy fees from BioCryst, CSL Behring, KalVista, Novartis, Pharming, Pharvaris, Sanofi, Shire-Takeda, and SOBI.A.J.C. reports no conflicts in relation to this manuscript.D.M.C reports speaking and/or consultancy fees from Astria, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Pharming, Pharvaris, and Takeda.D.C. reports no conflicts in relation to this manuscript.C.D. reports no conflicts in relation to this manuscript.A.F. has received honoraria from CSL Behring, Takeda and Torii, and a consulting fee from KalVista.M.H. has received speaker/consultancy fees for BioCryst, CSL Behring, KalVista, Pharvaris, Takeda, and Torii.C.H.K. reports speaking and/or consultancy fees from CSL Behring, Takeda, BioCryst, KalVista, Pharvaris, and Intellia, outside of the submitted work.P.H.L. reports speaking and/or consultancy fees from CSL Behring, KalVista, Pharvaris, and Takeda, outside of the submitted work.H.L. has collaborated in research and educational projects with, served as a speaker or advisor for, or received educational support from the following companies: CSL Behring, Intellia, KalVista, Pharvaris, Takeda.J.P. reports educational grant support from Takeda and speaking or advisory board fees from Astria, BioCryst, CSL Behring, KalVista, Pharvaris, and Takeda.F.P. reports speaking and/or consultancy fees from CSL Behring, Pharvaris, and Takeda.A.R. reports advisory boards and consultancy from BioCryst, CSL Behring, Ionis, Pharming, Pharvaris, and Takeda and received speaker’s honoraria from BioCryst, CSL Behring, and Takeda. Received research funding from BioCryst, CSL Behring, Ionis, Pharvaris, Shulov, and Takeda (formerly: Shire).B.R. reports conference travel support from CSL Behring, Octapharma, Takeda, and clinical trial support from CSL Behring.C.N.S. reports no conflicts in relation to this manuscript.A.Z. received speaker/consultancy fees from Astria, BioCryst, CSL Behring, KalVista, Otsuka, Pharming, Pharvaris, and Takeda.M.Mr. reports grants or speaker/advisor fees from Astria, BioCryst, CSL Behring, KalVista, Pharvaris and Takeda.